DermAvance Pharmaceuticals Announce Start of Pivotal Trials for DA-13-007 Dermal Filler

Malvern, Pa.  November  2014 – DermAvance Pharmaceuticals a privately held pharmaceutical company specializing in advanced technology applications for aesthetic products, today announced that the Food and Drug Administration (FDA)  has approved the Investigational Device Exemption (IDE) for DA-13-007-Dermal Filler to begin pivotal trials in the US.

Dermal Fillers are used to reverse changes associated with aging and can reduce or eliminate wrinkles and replace soft tissue volume loss, thus returning the dermis to its original youthful state.  Current marketed fillers include market leaders Juvederm. Restylane, Radiesse, and Sculptra.

“We are very pleased to begin this important pivotal trial of DA-13-007, a patent protected second generation dermal filler” says Keith Greathouse, DermAvance President and CEO.